Could N‐acetylcysteine improve the safety of clozapine?
Authors:
- 18 November 2020
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 36 (2)
Abstract
Clozapine is an atypical antipsychotic indicated in patients with treatment‐resistant schizophrenia which remains underused due to safety issues. Mechanisms behind these adverse effects are complex and not fully understood. They may involve immune‐related mechanisms, direct toxic effects and oxidative stress. Clozapine‐induced oxidative stress might indeed notably be involved in the onset of neutropenia, agranulocytosis, myocarditis, sialorrhea, and metabolic alterations. Therefore, the association of N‐acetylcysteine (NAC), an easily accessible, low‐cost and well tolerated antioxidant drug could be of interest in clozapine‐treated patients to improve clozapine safety. Furthermore, according to recent studies NAC could help to improve schizophrenia symptoms. We believe that the use of NAC in the context of clozapine prescribing merits further study, as it could improve clozapine safety which may lead to a wider use and ultimately improve the healthcare of thousands of patients. NAC could also secondarily show positive knock‐on effects for the patients by improving clinical symptoms of schizophrenia in synergy with clozapine, and by reducing substance abuse and thus by improving the patient's overall condition. However, given the rarity of clozapine‐induced severe adverse effects, only a large volume of data (e.g., National adverse events monitoring) could assess the benefits of NAC on clozapine safety.Keywords
This publication has 24 references indexed in Scilit:
- Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric populationThe Pharmacogenomics Journal, 2016
- Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B allelesNature Communications, 2014
- Protective effect of captopril against clozapine-induced myocarditis in rats: Role of oxidative stress, proinflammatory cytokines and DNA damageChemico-Biological Interactions, 2014
- N‐Acetylcysteine reduces early‐ and late‐stage cocaine seeking without affecting cocaine taking in ratsAddiction Biology, 2011
- N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionJournal of Psychiatry and Neuroscience, 2011
- Repeated N-Acetyl Cysteine Reduces Cocaine Seeking in Rodents and Craving in Cocaine-Dependent HumansNeuropsychopharmacology, 2010
- Role of Human GlutathioneS-Transferases in the Inactivation of Reactive Metabolites of ClozapineChemical Research in Toxicology, 2010
- Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
- Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterationsInternational Journal of Neuropsychopharmacology, 2008
- N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiencyCurrent Opinion in Pharmacology, 2007